GO
Loading...

Gilead Sciences Inc

More

  • US STOCKS-Wall St edges higher during earnings flurry Thursday, 17 Apr 2014 | 1:40 PM ET

    *Google, IBM shares fall a day after posting earnings. NEW YORK, April 17- U.S. stocks advanced slightly in choppy trading on Thursday after three days of gains, as underwhelming results from tech bellwethers Google and IBM were offset by upbeat quarterly numbers, including those from Morgan Stanley and General Electric.

  • April 17- UnitedHealth Group Inc, the largest U.S. health insurer, said on Thursday it has spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc, a higher cost than it expected by "multiples," sending shares in the sector lower.

  • The $9.4 billion Fidelity Select Biotechnology Fund plunged 11.75 percent during the first 14 days of April. That put the fund near the bottom among nearly 3,800 U.S. mutual funds tracked by Lipper Inc. Only six funds performed worse, but they had less than $100 million in assets each.

  • UnitedHealth's 1Q profit tumbles 8 percent Thursday, 17 Apr 2014 | 6:27 AM ET

    UnitedHealth Group's first-quarter net income slid 8 percent as funding cuts to a key product and costs imposed by the health care overhaul dented the health insurer's performance.

  • Final Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 6:02 PM ET

    Amgen Inc. rose$. 54 or. 5 percent, to $115.54. Biogen Idec rose $5.99 or 2.1 percent, to $291.48. Celgene Corp. rose $2.02 or 1.4 percent, to $141.86.

  • Midday Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 1:30 PM ET

    Amgen Inc. rose$. 17 or. 1 percent, to $115.17. Biogen Idec rose $5.59 or 2.0 percent, to $291.08. Celgene Corp. rose $1.52 or 1.1 percent, to $141.36.

  • Early Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 10:27 AM ET

    Amgen Inc. fell$. 34 or. 3 percent, to $114.67. Biogen Idec rose $2.08 or. 7 percent, to $287.57. Celgene Corp. rose $1.35 or 1.0 percent, to $141.19.

  • NEW YORK, April 16- Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive.

  • Report: Prescription drug spending climbs in 2013 Tuesday, 15 Apr 2014 | 12:09 PM ET

    Total U.S. prescription drug spending climbed more than 3 percent last year, propelled in part by fewer patent expirations that would have allowed for cheaper generic alternatives, according to the data firm IMS Health. IMS Health also noted that 36 new treatments entered the market last year, including 10 for cancer.

  • April 15- Johnson& Johnson reported quarterly earnings well above expectations, as strong sales of new drugs offset weak demand for consumer products and medical devices, and the company slightly raised its full-year profit view. J&J on Tuesday said it earned $4.73 billion, or $1.64 per share, in the first quarter.

  • Americans start spending on health care again Tuesday, 15 Apr 2014 | 7:06 AM ET

    Americans used more health services and spent more on prescription drugs in 2013, reversing a recent trend.

  • Spending on medicines rose 3.2 percent in the United States last year to $329.2 billion.

  • Final Glance: Biotechnology companies Monday, 14 Apr 2014 | 6:01 PM ET

    Amgen Inc. rose $1.38 or 1.2 percent, to $113.32. Biogen Idec rose $5.52 or 2.0 percent, to $279.52. Celgene Corp. rose $1.16 or. 8 percent, to $138.06.

  • Biotechs in the green after last week's carnage Monday, 14 Apr 2014 | 2:58 PM ET

    Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.

  • Midday Glance: Biotechnology companies Monday, 14 Apr 2014 | 2:08 PM ET

    Amgen Inc. rose $2.12 or 1.9 percent, to $114.06. Biogen Idec rose $6.40 or 2.3 percent, to $280.40. Celgene Corp. rose $1.64 or 1.2 percent, to $138.54.

  • Most active Nasdaq-traded stocks Monday, 14 Apr 2014 | 2:08 PM ET

    BlackBerry Ltd. fell 1.9 percent to $7.14 with 17,696,100 shares traded. Cisco Systems Inc. rose 1.7 percent to $22.85 with 35,296,700 shares traded. Facebook Inc. rose. 6 percent to $58.89 with 70,744,500 shares traded.

  • Early Glance: Biotechnology companies Monday, 14 Apr 2014 | 10:21 AM ET

    Amgen Inc. rose$. 01 or percent, to $111.95. Biogen Idec rose $3.06 or 1.1 percent, to $277.06. Celgene Corp. rose $1.60 or 1.2 percent, to $138.50.

  • Final Glance: Biotechnology companies Friday, 11 Apr 2014 | 6:02 PM ET

    Amgen Inc. fell $2.17 or 1.9 percent, to $111.94. Biogen Idec fell $13.35 or 4.6 percent, to $274.00. Celgene Corp. fell $3.08 or 2.2 percent, to $136.90.

  • Most active Nasdaq-traded stocks Friday, 11 Apr 2014 | 1:51 PM ET

    Cisco Systems Inc. fell. 8 percent to $22.46 with 47,023,900 shares traded. Facebook Inc. fell 1.1 percent to $58.53 with 85,527,500 shares traded. Gilead Sciences Inc. rose. 8 percent to $66.03 with 35,640,900 shares traded.

  • *JPMorgan falls, Wells Fargo gains after results. NEW YORK, April 11- U.S. stocks were little changed on Friday, as biotech stocks staged a rebound from a selloff in the prior session, but disappointing earnings from JPMorgan curbed gains.

Most Popular Video

Thursday, 17 Apr 2014 | 12:09 PM ET

CNBC's Scott Cohn reports Hampshire Hotel CEO Sant Singh Chatwal pleaded guilty in a campaign scheme.

Thursday, 17 Apr 2014 | 9:14 AM ET

CNBC's David Faber speaks with Weibo chairman Charles Chao, about Weibo's growth concerns and competition in the social space.

Thursday, 17 Apr 2014 | 8:15 AM ET

Nicole Miller Regan, Piper Jaffray, shares her thoughts on Chipotle's quarterly results, and discusses her $550 price target on the stock.